NCT07502469Completed
Study Comparing the Contribution of G-Eye Combined With CAD-Eye Versus High-definition Colonoscopy With CAD-Eye in the Detection of Colonic Lesions After a Positive Immunological Test in the Context of Organized Colorectal Cancer (BENEFIT)
Single-center, Retrospective Study Comparing the Contribution of G-Eye (Balloon-assisted Endoscopy) Combined With CAD-Eye (Artificial Intelligence Polyp Detection) Versus High-definition Colonoscopy With CAD-Eye in the Detection of Colonic Lesions After a Positive Immunological Test in the Context of Organized Colorectal Cancer Screening.
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
The incidence of colorectal cancer (CRC) is high in France, with approximately 45,000 new cases per year. The fecal immunochemical test (FIT) is used for screening for this cancer. If the test is positive, a colonoscopy is recommended. In recent years, French and European societies of digestive endoscopy have defined quality criteria for colonoscopy to reduce the risk of interval colorectal cancer (ICRC), that is, CRC occurring within 5 years of a colonoscopy considered negative. The operator's adenoma detection rate (ADR) is one of these factors. Its threshold is set at 45% within the framework of the organized CRC screening program, i.e., after a positive FIT. Artificial intelligence is emerging as an effective way to increase operators' ADR. Balloon-assisted endoscopy (G-Eye) also increases the TDA (transient anaerobic digestion). No French data are available regarding G-Eye, and there is limited data concerning CAD-Eye (artificial intelligence). No data exist on the combination of these two devices. Therefore, there is no data on the combination of these devices during a colonoscopy performed after a positive TIF (transient anaerobic digestion) test. It should be noted that all published studies were conducted in expert centers. The value of this study lies in its ability to collect real-world data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 341 (actual)
- First submitted
- 26 Mar 2026
- Start date
- 5 Nov 2024
- Primary completion date
- 1 Mar 2025
- Lead sponsor
- Elsan
- Diseases
- Colorectal cancer
- NCT number
- NCT07502469
What you commit to
- Study type: Observational
- Participants enrolled: 341
- From 5 Nov 2024 to the primary completion date, 1 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- High or very high risk of colorectal cancer (CRC) (inflammatory bowel disease, identified genetic predisposition to CRC, personal history of CRC, advanced adenoma \< 10 years, first-degree family history of CRC \< 60 years)
- Patient \< 50 years and \> 74 years
Other
- Patient opposed to the reuse of their health data
Who the study is looking for
- Fecal Immunological Test positive
- Age between 50 and 74 years
- Colonoscopy performed between November 1, 2021 and June 30, 2024
- Patient informed about the use of their health data
Age in the registry: 50 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinique Saint-françois Coordinator of this site? Confirm its status | Châteauroux | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.